GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biolidics Ltd (SGX:8YY) » Definitions » Net Income Including Noncontrolling Interests

Biolidics (SGX:8YY) Net Income Including Noncontrolling Interests : S$-3.49 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Biolidics Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Biolidics's Net Income Including Noncontrolling Interests for the three months ended in Dec. 2024 was S$-1.63 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2024 was S$-3.49 Mil.

Biolidics Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Biolidics's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolidics Net Income Including Noncontrolling Interests Chart

Biolidics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.65 -5.98 -9.37 -2.49 -3.43

Biolidics Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.94 -0.76 -0.69 -0.42 -1.63

Biolidics Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was S$-3.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biolidics Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Biolidics's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Biolidics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biolidics Ltd (SGX:8YY) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
SGX:1B1 SGX:505 SGX:P8A SGX:1H3 TMO DHR XSWX:LONN IDXX A SHSE:603259 IQV MTD NTRA WAT LH DGX XPAR:BIM ILMN XPAR:ERF EXAS
Traded in Other Exchanges
N/A
Address
18 Howard Road, No. 11-09 Novelty BizCentre, Singapore, SGP, 369585
Website
https://www.biolidics.com
Biolidics Ltd is engaged in technology development, technology transfer, marketing, sales, and distribution of biomedical technology, life, and medicine science-related products and services, and investment holding. The company's business segments are: Cancer, Infectious Diseases, E-sport, and Corporate. The company generates the majority of its revenue from E-sport segment, which involves identifying and assessing potential collaboration partners, technology, digital platforms, products, and services related to E-Sports.. Its operations are spread across Singapore, Japan, China, Europe, the United States, Hong Kong, the Philippines, Indonesia, and Others.

Biolidics Headlines

No Headlines